1. 1) Fitton A, Goa KI. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs, 50, 691–713 (1995).
2. 2) Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs, 63, 2029–2050 (2003).
3. 3) Ohtahara S, Fujiwara T, Kaneko S. lijima M. Clinical evaluation of lamotrigine with the current recommended dose in overseas—phase III study of lamotrigine in patients with epilepsy treated with valproate. New Rem Clin., 57, 1442–1453 (2008).
4. 4) “Pharmaceuticals and Medical Devices Safety Information No. 287.”: ‹http://www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/287.pdf›, cited 7 Aug. 2017.
5. 5) Yamada K. Optimization of pharmacotherapy and relief system for adverse drug reaction. Jpn J Clin Psychiatr., 42, 227–234 (2013).